| Abstract |
Ten patients with SSPE were surveyed during the last 4 years from the viewpoint of clinical safety for use of ribavirin therapy. Although effectiveness varied among cases, they were all treated safely with intraventricular ribavirin. This study suggests that treatment is safe and well-tolerated. |
| Authors | Akemi Tomoda, Keiko Nomura, Seiji Shiraishi, Akinobu Hamada, Takafumi Ohmura, Mitsuaki Hosoya, Teruhisa Miike, Yukio Sawaishi, Hiroshi Kimura, Hiroshi Takashima, Yoshihiro Tohda, Kenji Mori, Zenichiro Kato, Ai Fukushima, Hisanori Nishio, Akio Nezu, Kenji Nihei |
| Journal | Brain & development
(Brain Dev)
Vol. 25
Issue 7
Pg. 514-7
(Oct 2003)
ISSN: 0387-7604 [Print] Netherlands |
| PMID | 13129596
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antimetabolites
- Antiviral Agents
- Ribavirin
|
| Topics |
- Adolescent
- Adult
- Antimetabolites
(therapeutic use)
- Antiviral Agents
(administration & dosage, adverse effects, therapeutic use)
- Child
- Child, Preschool
- Female
- Humans
- Injections, Intraventricular
- Japan
- Male
- Ribavirin
(administration & dosage, adverse effects, therapeutic use)
- Subacute Sclerosing Panencephalitis
(drug therapy)
|
